DENTSPLY SIRONA (XRAY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.52
- Estimate
- $0.35
- Surprise
- +50.1%
- Revenue (period 2026-06-30)
- $898.0M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
DENTSPLY SIRONA (XRAY) beat the $0.35 estimate with adjusted EPS of $0.52 — a large 50.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XRAY Sell at 4.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +50.1% surprise compares with a +6.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (3.5 < 4.0)
- EARNINGS_PROXIMITY:7d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.44
- Price target
- $11.16
- Stop
- $8.78
- Upside to target
- +18.2%
- Reward-to-risk
- 1.5:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
XRAY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $1.88B
- P/E (fwd)
- 6.4
- 52-week range
- $8.32–$14.76
- Off 52-week high
- 36.0%
- RSI (14)
- 63
- Volume vs avg
- 0.81×
- Score today
- 4.8/10